Clinolipid 20% is a drug owned by Baxter Healthcare Corp. It is protected by 1 US drug patent filed in 2014 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 24, 2027. Details of Clinolipid 20%'s patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5840757 | Lipid emulsion intended for parenteral or enteral feeding |
Nov, 2015
(9 years ago) |
Expired
|
While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Clinolipid 20% and ongoing litigations to help you estimate the early arrival of Clinolipid 20% generic.
Clinolipid 20%'s Litigations
Clinolipid 20% been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jan 01, 1, against patent number US5840757. The petitioner , challenged the validity of this patent, with DUTOT as the respondent. Click below to track the latest information on how companies are challenging Clinolipid 20%'s patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US5840757 | January, 1 |
Decision
(29 Jul, 1998) | DUTOT | |
FDA has granted some exclusivities to Clinolipid 20%. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Clinolipid 20%, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Clinolipid 20%.
Exclusivity Information
Clinolipid 20% holds 2 exclusivities out of which 1 have expired. Its last outstanding exclusivity is set to expire in 2027. Details of Clinolipid 20%'s exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 03, 2016 |
| New Patient Population(NPP) | Apr 24, 2027 |
US patents provide insights into the exclusivity only within the United States, but Clinolipid 20% is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Clinolipid 20%'s family patents as well as insights into ongoing legal events on those patents.
Clinolipid 20%'s Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Clinolipid 20%'s generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Apr 24, 2027 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Clinolipid 20% Generics:
There are no approved generic versions for Clinolipid 20% as of now.
About Clinolipid 20%
Clinolipid 20% is a drug owned by Baxter Healthcare Corp. Clinolipid 20% uses Olive Oil; Soybean Oil as an active ingredient. Clinolipid 20% was launched by Baxter Hlthcare Corp in 2013.
Approval Date:
Clinolipid 20% was approved by FDA for market use on 03 October, 2013.
Active Ingredient:
Clinolipid 20% uses Olive Oil; Soybean Oil as the active ingredient. Check out other Drugs and Companies using Olive Oil; Soybean Oil ingredient
Dosage:
Clinolipid 20% is available in emulsion form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 16%(160GM/1000ML);4% (40GM/1000ML) | EMULSION | Prescription | INTRAVENOUS |